News and Events
Boyd Martin Repeats Victory at $75,000 Asheville Regional Airport Wellington Eventing Showcase, Presented By Wellington Equestrian Realty
Wellington, FL – February 6, 2016 – Boyd Martin (USA) piloted new mount Blackfoot Mystery to victory in the $75,000 Asheville Regional Airport Wellington Eventing Showcase, presented by Wellington Equestrian Realty, held at The Stadium at Palm Beach International Equestrian Center and produced by Equestrian Sport Productions (ESP). Martin bested a class of 35 entries with a final score of 30.60. Colleen Rutledge (USA) and Covert Rights finished in second place with a 31.00, while Daniel Jocelyn (NZL) rode catch-ride Devil Munchkin to third with a score of 32.30.
The 2016 event proved to be the most successful yet, as a large crowd of spectators and fans packed the Global Pavilion and lined the fences of the polo and derby fields used to host cross-country competition. Martin and Blackfoot Mystery, owned by the Blackfoot Mystery Syndicate, jumped to an early lead after going clear in the show jumping phase around the difficult track set by Richard Jeffrey. They then continued fault-free on cross country to earn a double clear effort. The cross country track was designed by Captain Mark Phillips and was built by Eric Bull of ETB Equine Construction. Read the press release


Todd Minikus and Babalou 41 Win $130,000 Adequan® Grand Prix CSI 3* at the 2016 Winter Equestrian Festival Richard Spooner and Mighty Mouse Take $35,000 Douglas Elliman 1.45m Classic; Emma Kurtz Dominates the Charleigh’s Cookies Large Junior Hunter 15 & Under Division Aboard Fredrick Lauren Fisher and Callie Seaman for Jennifer Wood Media, Inc. Wellington, FL – January 30, 2016 – For the second week in a row, USA’s Todd Minikus was the big winner of the Saturday night grand prix at the 2016 Winter Equestrian Festival (WEF). During week two of the winter circuit, held at the Palm Beach International Equestrian Center (PBIEC), Minikus topped the $86,000 Marshall & Sterling Insurance Grand Prix CSI 2* riding Quality Girl. For his win in week three, the rider guided Babalou 41 to a thrilling victory in the $130,000 Adequan® Grand Prix CSI 3*. Laura Kraut (USA) and Nouvelle finished second, and Chloe Reid (USA) and Codarco placed third.

Week three of the Winter Equestrian Festival, sponsored by Adequan®, concludes on Sunday, January 31, with the $35,000 Suncast® 1.50m Championship Jumper Classic. The 12-week WEF circuit runs through April 3 offering more than $9 million in prize money.
Read the press release


LUITPOLD ANIMAL HEALTH, MAKER OF ADEQUAN®, NAMED OFFICIAL PARTNER OF BREEDERS’ CUP WORLD CHAMPIONSHIPS
LEXINGTON, Ky. (October 7, 2015) – Luitpold Animal Health, maker of Adequan® (polysulfated glycosaminoglycan) and a leading manufacturer of animal health products, has been named an official partner in the Equine Joint Wellness category of the Breeders’ Cup World Championships.
The Breeders’ Cup, Thoroughbred racing’s most prestigious two-day championship event, featuring 13 grade one races with purses and awards totaling $26 million, will be held on October 30-31 at Keeneland Race Course in Lexington. Read the press release


AQHA Expands Level 2 Championships
The success of the inaugural Level 2 amateur and open championships ushers in new opportunities for Select and Youth exhibitors. The American Quarter Horse Association When the Adequan® (polysulfated glycosaminoglycan) Level 2 championship classes launched at the 2015 Lucas Oil AQHA World Championship Show in Oklahoma City, their debut was met with enthusiasm from exhibitors, owners and professionals. In fact, the addition of the Adequan® Level 2 classes increased Lucas Oil World entries by 32 percent over the previous year.
Read the press release


Adequan® Signs On As Presenting Sponsor of Land Rover Great Meadow International for Three Years
The Plains, Virginia - May 18, 2015 - The Land Rover Great Meadow International is delighted to welcome Adequan® i.m. (polysulfated glycosaminoglycan) as presenting sponsor for the next three years. The event will now be known as The Land Rover Great Meadow International presented by Adequan®, and takes place at Great Meadow in The Plains, Virginia, June 19-21, 2015.
Located in the heart of the Virginia countryside, The Land Rover Great Meadow International presented by Adequan® will feature a $30,000 CIC3* competition and will host the Land Rover U.S. Eventing Team for its final preparation trial prior to the 2015 Pan American Games in Toronto, Canada this summer. Read the press release







Adequan® i.m. INDICATIONS For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. IMPORTANT SAFETY INFORMATION Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Adequan® I.A. INDICATIONS For the intra-articular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. IMPORTANT SAFETY INFORMATION Inflammatory joint reactions and septic arthritis have been reported following administration of Adequan® I.A. Joint sepsis, a rare but potentially life threatening complication, can occur after intra-articular injection. Use only in the carpal joint of horses. WARNING: Do not use in horses intended for human consumption. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
BetaVet® INDICATIONS BetaVet® is indicated for the control of pain and inflammation associated with osteoarthritis in horses. IMPORTANT SAFETY INFORMATION For Intra-articular (I.A.) use in Horses. CONTRAINDICATIONS: BetaVet® is contraindicated in horses with hypersensitivity to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis. WARNINGS: Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have resulted in cleft palate in offspring and in other congenital anomalies including deformed forelegs, phocomelia and anasarca. Therefore, before use of corticosteroids in pregnant animals, the possible benefits to the pregnant animal should be weighed against potential hazards to its developing embryo or fetus. Human Warnings: Not for use in humans. For use in animals only. Keep this and all medications out of the reach of children. Consult a physician in the case of accidental human exposure. PRECAUTIONS: Corticosteroids, including BetaVet®, administered intra-articularly are systemically absorbed. Do not use in horses with acute infections. Acute moderate to severe exacerbation of pain, further loss of joint motion, fever, or malaise within several days following intra-articular injection may indicate a septic process. Because of the anti-inflammatory action of corticosteroids, signs of infection in the treated joint may be masked. Due to the potential for exacerbation of clinical signs of laminitis, glucocorticoids should be used with caution in horses with a history of laminitis, or horses otherwise at a higher risk for laminitis. Use with caution in horses with chronic nephritis, equine pituitary pars intermedia dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs, such as NSAIDs or other corticosteroids, should be approached with caution. Due to the potential for systemic exposure, concomitant use of NSAIDs and corticosteroids may increase the risk of gastrointestinal, renal, and other toxicity. Consider appropriate wash out times prior to administering additional NSAIDs or corticosteroids. ADVERSE REACTIONS: Adverse reactions reported during a field study of 239 horses of various breeds which had been administered either BetaVet® (n=119) or a saline control (n=120) at five percent (5%) and above were: acute joint effusion and/or local injection site swelling (within 2 days of injection), 15% BetaVet® and 13% saline control; increased lameness (within the first 5 days), 6.7% BetaVet® and 8.3% saline control; loose stool, 5.9% BetaVet® and 8.3% saline control; increased heat in joint, 2.5% BetaVet® and 5% saline control; and depression, 5.9% BetaVet® and 1.6% saline control. DOSAGE AND ADMINISTRATION: Shake well immediately before use. Use immediately after opening, then discard any remaining contents. Use immediately after opening, then discard any remaining contents. RX ONLY


Online ordering system for veterinarians Purchase Adequan® and BetaVet® Online Now! Or Call Customer Service Today!
(800) 458-0163
Online ordering system for veterinarians Purchase Adequan® and BetaVet® Online Now!

Or Call Customer Service Today! (800) 458-0163


Copyright © 2016 Luitpold Pharmaceuticals, Inc. All rights reserved.
Adequan®, BetaVet® and the Horse Head design are registered trademarks of Luitpold Pharmaceuticals, Inc.
©Luitpold Animal Health, division of Luitpold Pharmaceuticals, Inc. 2016. Luitpold Animal Health website, PP-AA-US-0007 10/2016